Global Cancer Vaccine Market & Clinical Trial Insight 2025

“Global Cancer Vaccine Market & Clinical Trial Insight 2025”  Report Highlight:

• Global Cancer Vaccine market Opportunity: US$ 15 Billion opportunity
• Personalized Cancer Vaccine: The Next growth Frontier
• Global Cancer Vaccine Clinical insight by Indication & Phase of Development
• Global Cancer Vaccine Pipeline: 369 Cancer Vaccines
• Marketed Cancer Vaccines: 17 Cancer Vaccines
• Maximum Vaccines in Pipeline for Brain & Breast Cancer:  43 Cancer Vaccines
• Regulatory Landscape

Global cancer vaccine market opportunity is expected to surpass US$ 15 Billion by 2025 as per finding in new research report “Global Cancer Vaccine Market & Clinical Trial Insight 2025” published by PNS Pharma. In recent years, cancer vaccine segment as emerged as next growth frontier for the various stake holders involved in the research, development and commercialization of  cancer therapeutics. The market for cancer therapeutics is growing at significant rates and it has already occupied a major share in the overall pharmaceutical market.

 

Download Report:

http://www.pnspharma.com/buy-report.php?reporttitle=Global-Cancer-Vaccine-Market-%26-Clinical-Trial-Insight-2025

For Sample Contact: rajesh@pnspharma.com

 

Report TOC

 

1. Introduction to Cancer Vaccines

 

2. Mechanism of Cancer Vaccines

2.1 Idiotype Cancer Vaccine Mechanism

2.2 Cellular Cancer Vaccines Mechanism

2.3 Ganglioside Antigens based Cancer Vaccines Mechanism

2.4 Peptide Cancer Vaccine Mechanism

2.5 Tumor Host Interaction Cancer Vaccine Mechanism

 

3. Global Cancer Vaccines Market Overview

3.1 Current Scenario

3.2 Future Outlook

 

4. Personalized Cancer Vaccine: The Next growth Frontier

4.1 The Possibility of a Personalized Cancer Vaccine

4.2 An Insight into its Current Clinical Status

 

5. Personalized Cancer Vaccine: Current Market Scenario & Advancements

5.1 Breakthrough in Research & Development

5.2 Increasing Investments

5.3 Integration of mRNA Technology

5.4 Collaborations & Ventures

5.5 Advancement in Technology

 

6. FDA Guideline for the Development & Marketing of Cancer Vaccines

6.1 Considerations for Both Early and Late Phase Clinical Trials

6.1.1 Patient Population

6.1.2 Monitoring The Immune Response

6.1.3 Biomarkers As Evidence Of Efficacy

6.1.4 Adjuvants Used To Stimulate Immune Response

6.1.5 Multi-Antigen Vaccines

6.1.6 Disease Progression/Recurrence Immediately Or Shortly After The Initial Administration Of Cancer Vaccines

6.1.7 Concomitant And Subsequent Therapies

6.2 Considerations for Early Phase Clinical Trials

6.2.1 Starting Dose And Dosing Schedule

6.2.2 Booster And Maintenance Therapy

6.2.3 Dose Escalation

6.2.4 Single-Arm Versus Randomized Phase 2 Trials In Early Development

6.3 Considerations For Late Phase Clinical Trials

6.3.1 Safety Profile From Early Phase Clinical Trials

6.3.2 Endpoints

6.3.3 Statistical Issues

6.3.4 Control Issues

6.3.5 Delayed Vaccine Effect

6.3.6 Autologous Vaccine Trials

6.3.7 Accelerated Approval Regulations

 

7. Global Cancer Vaccines Clinical Pipeline Overview

7.1 By Indication

7.2 By  Mechanism of Action

7.3 By  Drug Class

7.4 By Patient Segment

7.5 By Formulation

7.6 By  Company

 

8. Global – Bladder Cancer Vaccine Clinical Pipeline by Phase & Company

8.1 Phase-I/II

 

9. Marketed Bladder Cancer Vaccine Clinical Insight

9.1 BCG Bladder Cancer Vaccine – sanofi pasteur

9.2 Bladder Cancer Vaccine – Organon Teknika

9.3 Bladder Cancer Vaccine – ID Biomedical

 

10. Global – Blood Cancer Vaccine Clinical Pipeline by Phase & Company

10.1 Research

10.2 Preclinical

10.3 Phase-I

10.4 Phase-I/II

10.5 Phase-II

 

11. Global – Bone Cancer Vaccine Clinical Pipeline by Phase & Company

11.1 Phase-II

11.2 Phase-III

 

12. Global – Brain Cancer Vaccine Clinical Pipeline by Phase & Company

12.1 Unknown

12.2 Research

12.3 Preclinical

12.4 Phase-I

12.5 Phase-I/II

12.6 Phase-II

12.7 Phase-III

 

13. Global – Breast Cancer Vaccine Clinical Pipeline by Phase & Company

13.1 Research

13.2 Preclinical

13.3 Phase-I

13.4 Phase-I/II

13.5 Phase-II

13.6 Phase-II/III

13.7 Phase-III

 

 

14. Global – Cervical Cancer Vaccine Clinical Pipeline by Phase & Company

14.1 Preclinical

14.2 Clinical

14.3 Phase-I

14.4 Phase-II

14.5 Phase-III

 

15. Marketed Cervical Cancer Vaccine Clinical Insight

15.1 Cervarix

 

16. Global – Colorectal Cancer Vaccine Clinical Pipeline by Phase & Company

16.1 Research

16.2 Preclinical

16.3 Phase-I

16.4 Phase-I/II

16.5 Phase-II

16.6 Phase-II/III

16.7 Phase-III

 

17. Global – Kidney Cancer Vaccine Clinical Pipeline by Phase & Company

17.1 Preclinical

17.2 Phase-I

17.3 Phase-II

17.4 Phase-III

 

18. Marketed Kidney Cancer Vaccine Clinical Insight

18.1 Vitespen (Oncophage)

18.2 Dendritic Cell Vaccine (CreaVax-HCC, CreaVax-PC & CreaVax-RCC)

18.3 Renal Cell Carcinoma Vaccine (Reniale)

 

 

19. Global – Liver Cancer Vaccine Clinical Pipeline by Phase & Company

19.1 Phase-I/II

19.2 Phase-II

19.3 Phase-III

 

20. Global – Lung Cancer Vaccine Clinical Pipeline by Phase & Company

20.1 Preclinical

 

21. Global – Mesothelioma Vaccine Clinical Pipeline by Phase & Company

21.1 Phase-I

21.2 Phase-II/III

 

22. Global – Head And Neck Cancer Vaccine Clinical Pipeline by Phase & Company

22.1 Preclinical

22.2 Phase-I

22.3 Phase-I/II

22.4 Phase-II

 

23. Global – Non Small Cell Lung Cancer Vaccine Clinical Pipeline by Phase & Company

23.1 Research

23.2 Clinical

23.3 Phase-I

23.4 Phase-I/II

23.5 Phase-II

23.6 Phase-II/III

23.7 Phase-III

23.8 Preregistration

 

24. Marketed Non Small Cell Lung Cancer Vaccine Clinical Insight

24.1 Cadi 05 (Immuvac & Mycidac-C)

24.2 Racotumomab (Vaxira)

24.3 Epidermal Growth Factor Cancer Vaccine – Bioven

 

25. Global – Ovarian Cancer Vaccine Clinical Pipeline by Phase & Company

25.1 Preclinical

25.2 Phase-I

25.3 Phase-I/II

25.4 Phase-II

25.5 Phase-III

 

26. Global – Prostate Cancer Vaccine Clinical Pipeline by Phase & Company

26.1 Research

26.2 Preclinical

26.3 Phase-I

26.4 Phase-I/II

26.5 Phase-II

26.6 Phase-III

 

27. Marketed Prostate Cancer Vaccine Clinical Insight

27.1 Sipuleucel-T (Provenge)

 

28. Global – Pancreatic Cancer Vaccine Clinical Pipeline by Phase & Company

28.1 Preclinical

28.2 Phase-I

28.3 Phase-I/II

28.4 Phase-II

28.5 Phase-III

 

 

29. Marketed Pancreatic Cancer Vaccine Clinical Insight

29.1 Tertomotide (LucaVax)

 

30. Global – Skin Cancer Vaccine Clinical Pipeline by Phase & Company

30.1 Preclinical

30.2 Phase-I

30.3 Phase-I/II

30.4 Phase-II

30.5 Phase-III

30.6 Preregistration

 

31. Marketed Skin Cancer Vaccine Clinical Insight

31.1 Melanoma Vaccine (MVax)

31.2 Melanoma Vaccine (Melacine)

 

32. Global – Multiple Cancer Vaccine Clinical Pipeline by Phase & Company

32.1 Research

32.2 Preclinical

32.3 Clinical

32.4 Phase-I

32.5 Phase-I/II

32.6 Phase-II

32.7 Phase-III

32.8 Registered

 

33. Marketed Multiple Cancer Vaccine Clinical Insight

33.1 Human Papillomavirus Vaccine Recombinant Nonavalent (GARDASIL9)

33.2 Human Papillomavirus Vaccine Recombinant Quadrivalent (Gardasil & Silgard)

33.3 Dendritic Cell-Activated Cytokine-Induced Killer Cells – Shanghai Jia Fu Medical

 

 

34. Competitive Landscape

34.1 Advaxis

34.2 AVAX Technologies

34.3 Dendreon Corporation

34.4 Galena Biopharma

34.5 GlaxoSmithKline

34.6 ImmunoCellular Therapeutics

34.7 ImmunoGen

34.8 Inovio Pharmaceuticals

34.9 KAEL-GemVax

34.10 Liponova

34.11 MedImmune

34.12 Merck

34.13 NeoStem Oncology

34.14 NewLink Genetics

34.15 Northwest Biotherapeutics

34.16 Novartis

34.17 Peregrine Pharmaceuticals

34.18 Recombio

34.19 Roche

34.20 Sanofi

34.21 Seattle Genetics

34.22 Valeant Pharmaceuticals